Skip to Main Content

Rise and shine, everyone, another busy and challenging day is on the way. And though the days may seem to blur together lately, this is already the middle of the week. Depending on your perspective, this may be cause to acknowledge some progress, however modest, at forging ahead under difficult circumstances. So treat yourself to a cup of stimulation. Our own choice today is the ever-tasty maple bourbon. Meanwhile, here are some tidbits to guide you on your journey. Stay in touch and stay safe. …

Biogen (BIIB) pushed back the regulatory filing for its hotly debated Alzheimer’s drug candidate, aducanumab, until the third quarter of this year, following a scheduled meeting with FDA officials this summer, STAT reports. “We believe this underscores the complexity of the data and its interpretation, and would likely place completion of regulatory review well beyond the timelines of the general election,” wrote RBC Capital Markets analysts in an investor note.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!